Diagnostic agent and medicine comprising ADAMTS13 as main ingredient
New use of ADAMTS13 in the clinical filed is provided. The use of ADAMTS13 as a biomarker for monitoring the onset of liver damage, hepatic ischemia/reperfusion injury or the liver function after liver transplantation: a method of testing liver damage, a method of testing hepatic ischemia/reperfusion injury, or a method of testing the liver function after liver transplantation, each of the methods comprising measuring or monitoring the ADAMTS13 activity in a sample from a mammal; an agent for treating diseases selected from the group consisting of liver damage, hepatic ischemia/reperfusion injury and hepatic dysfunction after liver transplantation, which comprises ADAMTS13 or a mutant of ADAMTS13 as an effective ingredient.
1. A method of testing and treating a disorder of hepatic non-parenchymal cells, comprising:
measuring or monitoring the ADAMTS13 activity in a sample from a mammal, wherein the disorder of hepatic non-parenchymal cells is a disorder after chemotherapy of colorectal cancer, and wherein the mammal is diagnosed with the disorder of hepatic non-parenchymal cells when a decrease in the ADAMTS13 activity in the sample is observed as compared to the ADAMTS13 activity in a sample from a healthy subject, and
treating the mammal diagnosed with the disorder of hepatic non-parenchymal cells by administering ADAMTS13 or a mutant of ADAMTS13 having ADAMTS13 activity as an effective ingredient, or a pharmaceutical composition comprising ADAMTS13 or a mutant of ADAMTS13 having ADAMTS13 activity as an effective ingredient.
2. The method of claim 1 , wherein the mammal is human.
3. The method of claim 1 , wherein the sample from a mammal is blood from a mammal.
4. The method of claim 1 , wherein the mutant of ADAMTS13 is a molecule comprising a minimum unit necessary for exerting ADAMTS13 activity, wherein the minimum unit consists of a portion of ADAMTS13 from the metalloprotease domain to a spacer domain.
5. The method of claim 4 , wherein the mutant of ADAMTS13 is a C-terminus deficient mutant W688X (ADAMTS13W688X protein) which is a resultant of deletion of the C-terminal portion from the amino acid at position 689 from ADAMTS13 consisting of 1427 amino acid residues.
6. The method of claim 1 , wherein the administration of ADAMTS13 or the mutant of ADAMTS13 is systemic administration or topical administration.
7. The method of claim 6 , wherein systemic administration is selected from the group consisting of oral, subdermal, intramuscular, intraperitoneal, subcutaneous, nasal, sublingual and rectal administration.
8. The method of claim 1 , wherein the pharmaceutical composition is administered orally and is selected from the group consisting of tablets, capsules, powders, and liquids.
9. The method of claim 8 , wherein the tablets comprise ADAMTS13 or a mutant of ADAMTS13 having ADAMTS13 activity, and gelatin or adjuvants.
10. The method of claim 8 , wherein the liquids comprise ADAMTS13 or a mutant of ADAMTS13 having ADAMTS13 activity, and a liquid carrier selected from the group consisting of water, petroleum, animal oils, vegetable oils, mineral oils, synthetic oils, saline, a solution of glucose, a solution of ethylene glycol, a solution of propylene glycol, and a solution of polyethylene glycol.
11. The method of claim 1 , wherein the pharmaceutical composition is administered by intravenous, cutaneous, or subcutaneous injection, and the pharmaceutical composition comprises ADAMTS13 or a mutant of ADAMTS13 having ADAMTS13 activity, and a solution comprising at least one additional component selected from the group consisting of isotonic media, a preservative, a stabilizing agent, a buffer, an antioxidant and other pharmaceutically acceptable additives.
12. The method of claim 1 , wherein the pharmaceutical composition is administered in an amount of 100 to 700 units/kg body weight by intravenous injection, intramuscular injection, or subcutaneous injection, and is administered one or more times.